Lennox-Gastaut Syndrome Drug Market By Mechanism of Action (Anti-Epileptics, Anticonvulsants and Others), Drugs (Valproic Acid, Topiramate, Felbamate, Rufinamide, Lamotrigine and Others), Treatment (Medication, Dietary Therapy and Surgery), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2026
Market Analysis: Global Lennox-Gastaut Syndrome Drug Market
Global Lennox-Gastaut syndrome drug market is growing at a substantial CAGR in the forecast period of 2021-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the rising population with risk factors for LGS, the growing prevalence of infectious diseases such as encephalitis and meningitis will further increase the risk of the development of LGS, initiatives taken by government and non-governmental organizations for raising awareness about this syndrome, increasing investment of biotechnology and pharmaceutical industries in R&D and increasing healthcare expenditure are some of the factors fueling the market growth.
Download full sample report of Lennox-Gastaut syndrome drug market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-lennox-gastaut-syndrome-drug-market
Market Definition: Global Lennox-Gastaut Syndrome Drug Market
Lennox-Gastaut syndrome (LGS) is a rare type of childhood onset epilepsy that progresses during early stages of childhood. Patients with this syndrome have developmental delay, behavioral problems and different types of seizures such as atonic, tonic and atypical absence seizures.
This syndrome is associated with several gene mutations, perinatal insults, congenital infections, brain tumors/malformations and genetic disorders such as tuberous sclerosis and West syndrome.
According to National Organization for Rare Disorders (NORD), it estimates that Lennox-Gastaut syndrome occur in 1-28 people per 100,000 and it accounts for 1-4 percent of all cases of childhood epilepsy. The annual incidence of this syndrome in children is estimated to be 2 per 100,000 children.
Market Drivers
Rising population with risk factors for LGS is driving the market growth
Growing prevalence of infectious diseases such as encephalitis and meningitis increases the risk of the development of LGS which acts as a market driver
Increasing investment of biotechnology and pharmaceutical industries in R&D is enhancing the market growth
Initiatives taken by government and non-governmental organizations for raising awareness amongst people about this disorder also boost the market growth
Increasing global healthcare expenditure drives the market growth
Market Restraints
Side effects associated with available treatment is hampering the market growth
High cost of treatment available is restraining the market growth
Lack of availability of essential services in remote areas acts as a market restraint
Segmentation: Global Lennox-Gastaut Syndrome Drug Market
By Mechanism of Action
- Anti-Epileptics
- Anticonvulsants
- Others
By Drugs
- Valproic Acid
- Topiramate
- Felbamate
- Rufinamide
- Lamotrigine
- Others
By Treatment
- Medication
- Dietary Therapy
- Surgery
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
By Geography
- North America
- S.
- Canada
- Mexico
- Europe
- Germany
- Italy
- K.
- France
- Spain
- Netherlands
- Belgium
- Switzerland
- Turkey
- Russia
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Malaysia
- Thailand
- Indonesia
- Philippines
- Rest of Asia Pacific
- South America
- Brazil
- Rest of South America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Key Developments in the Market
In November 2018, Aquestive Therapeutics, Inc received the U.S FDA approval for Sympazan (clobazam) for the treatment of Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older. Patients with LGS have difficulty in swallowing tablets or large volumes of oral suspension, because of physical limitations or compliance issues, Sympazan oral film is a cost effective treatment and will overcome difficulties in those patients who faces difficulty in swallowing tablets
In June 2018, GW Pharmaceuticals plc received the U.S FDA approval for Epidiolex (cannabidiol), oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older. This approval proves that properly evaluating the active ingredients contained in marijuana can lead to important medical therapies
Competitive Analysis:
Global Lennox-Gastaut syndrome drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Lennox-Gastaut syndrome drug for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
The key market players in the global Lennox-Gastaut syndrome drug market are Pfizer Inc, Sunovion Pharmaceuticals Inc, Novartis AG, Abbott, Eisai Co., Ltd, INSYS THERAPEUTICS, INC, GW Pharmaceuticals plc, Johnson & Johnson Services, Inc, GlaxoSmithKline plc, Zogenix, H. Lundbeck A/S, Bausch Health, Supernus Pharmaceuticals, Inc, UCB Pharma Ltd, Sanofi, Marinus Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd among others.
Get full details of TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-lennox-gastaut-syndrome-drug-market
Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-lennox-gastaut-syndrome-drug-market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com
Browse Related Reports @